Before assuming non-response to antipsychotic treatment
Thursday 25th August 2022, 2 PM (Central European Summer Time) Duration 120 minutes
Schizophrenia is a mental disorder characterized by
contiuous or relapsing episodes of psychosis.
Symptoms typically come on gradually, begin in young adulthood, and in many cases never resolve. About half of those diagnosed with schizophrenia will have a significant improvement over the long term with no further relapses, and a small proportin of these will recover completely. The other half will have a lifelong impairment. In some cases, people may be repeatedly admittd to hospitals. Social problems such as long-term unemployment, poverty, homelessness, exploitatin, and victiizatin are commonly correlated with schizophrenia. The mainstay of treatment is antisychoti medicatin, along with counselling and social rehabilitatin. The WPA webinars on schizophrenia management will be addressed mainly to the clinical doctors, who would like to enrich their pract
cal experience in the treatment of schizophrenia in order to bring our patints back to their families and even to their job.
Our Faculties are:
Prof. Dr. Peter Falkai, Department of Psychiatry and Psychotherapy, LudwigMaximilians University Hospital, Munich, Germany
Prof S. Hjorth, Professor of Pharmacology. CEO Pharmacilitator AB, Sweden
Thursday 25th August 2022, 2 PM Central European Summer Time
02:00 pm – 02:07 pm: Welcome address - Prof Afzal Javed
02:15 pm – 03:00 pm: Prof P. Falkai What is non-response and how to address it?
03:00 pm – 03:45 pm: Prof S. Hjorth The more, the merrier…? Antisychoti polypharmacy in schizophrenia
03:45 pm – 04:00 pm: Question and Answer
For all Enquiries please email firstname.lastname@example.org
Free access to the webinar. For Registration, please click here: Proceed for Registration
Participants can receive a CPD Certificate on complimentary basis (on request) after attending the Webinar.
This meeting has been supported by a financial grant, for educational purposes, from Gedeon Richter Plc and Recordati S.P.A. No influence has been exerted on the Agenda or its materials.